N4 Pharma hails positive results in inflammatory bowel disease study
12th May 2025 11:37
(Alliance News) - N4 Pharma PLC shares jumped on Monday as it reported positive results from the first in vivo study of its proprietary gene delivery system Nuvec for inflammatory bowel disease. Read More